How do you future-proof a laboratory automation investment?

A laboratory automation investment is future-proofed by choosing systems that adapt to evolving regulations, scale with increasing sample volumes, support multiple analyte classes, and reduce dependency on hazardous solvents. The most durable investments combine technical flexibility with vendor stability and genuine sustainability credentials. The questions below unpack each of these dimensions in detail.

What makes a laboratory automation system truly future-proof?

A truly future-proof laboratory automation system is one that can accommodate regulatory shifts, expanded analyte panels, higher throughput demands, and greener chemistry requirements without requiring full replacement. It is modular, vendor-supported over the long term, compatible with established analytical standards, and designed to handle multiple sample matrices from day one.

Future-proofing is not a single feature; it is a combination of design decisions. Systems built around open architectures allow laboratories to add modules or upgrade components as workflows evolve. Compatibility with EPA, CEN, and ISO method frameworks means the platform remains valid when regulators update analytical requirements. And because the analytical landscape for persistent organic pollutants continues to expand, systems that already handle dioxins, PCBs, PFAS, PBDEs, and pesticides across matrices such as food, feed, soil, water, and air give laboratories the broadest possible foundation.

The operational model of the vendor also matters. A supplier that offers method development support, training, and ongoing technical assistance extends the effective lifespan of the equipment far beyond what the hardware alone could achieve.

How do regulatory changes affect automated sample preparation workflows?

Regulatory changes affect automated sample preparation workflows primarily by expanding the list of target compounds, tightening detection limits, and introducing new approved methods that existing systems must accommodate. Laboratories that invested in rigid, single-analyte platforms often face costly revalidation or equipment replacement when regulations shift.

The regulatory environment for environmental contaminants has intensified steadily. PFAS regulations in particular have moved rapidly in Europe and North America, with authorities progressively lowering tolerable intake values and expanding the number of regulated compounds. Similarly, updated EU directives on dioxins and PCBs in food and feed have pushed laboratories toward higher sensitivity and tighter quality control requirements.

Automated platforms that support flexible method programming and cartridge interoperability absorb these changes more easily. When a system can switch between analyte classes or matrices by adjusting software parameters rather than replacing hardware, the cost of regulatory compliance drops significantly. This is why laboratories evaluating SPE automation systems increasingly prioritize configurability alongside raw throughput.

What’s the difference between scalable and non-scalable lab automation?

Scalable lab automation allows a laboratory to increase sample throughput, add analyte coverage, or expand matrix capability without replacing the core system. Non-scalable automation is optimized for a fixed workflow and becomes a bottleneck or liability as demand grows or requirements change.

The distinction becomes visible in real-world operation. A non-scalable system might process a fixed number of samples per run, accept only one cartridge format, or require dedicated hardware for each analyte class. When sample volumes increase or a new contaminant class enters the testing scope, the laboratory must either purchase an entirely new platform or run parallel systems that create logistical complexity.

What scalability looks like in practice

Scalable systems offer multi-channel configurations, support for a range of cartridge sizes, and compatibility with different sample volumes. A platform that can process large batches across consecutive sequences, handle cartridges from 1 mL to 12 mL, and manage sample volumes from 10 mL up to 1,000 mL provides genuine headroom for growth. Switching between small- and large-volume racks without instrument downtime is a concrete indicator of scalable design.

Why scalability affects laboratory automation ROI

Laboratory equipment ROI is directly tied to how long a system remains fit for purpose. A scalable platform that serves the laboratory across five or ten years of evolving demand delivers far greater return than a cheaper, rigid system that requires replacement within three. When evaluating automated sample preparation systems, the total cost of ownership over a realistic operational horizon is a more meaningful metric than the purchase price alone.

How does solvent reduction technology extend the lifespan of lab investments?

Solvent reduction technology extends the lifespan of laboratory automation investments by decreasing mechanical wear, reducing the risk of instrument contamination, lowering running costs, and positioning the laboratory ahead of tightening occupational health and environmental regulations that are progressively restricting high-volume solvent use.

Systems that operate with less than 100 mL of organic solvent per sample and that eliminate dichloromethane entirely place fewer chemical stresses on instrument components over time. Seals, valves, and flow paths degrade faster when exposed to aggressive solvents at high volumes. Reducing solvent load therefore has a direct mechanical benefit alongside the more obvious safety and sustainability advantages.

There is also a regulatory dimension. Dichloromethane is subject to increasingly strict controls under occupational safety legislation in Europe, and laboratories that have already transitioned away from it face no disruption when restrictions tighten further. Investing in low-solvent automated sample preparation now is not just an environmental choice; it is a hedge against future compliance costs.

The sustainability argument reinforces the financial one. Green laboratory automation reduces waste disposal costs, lowers the procurement burden for expensive high-purity solvents, and supports corporate sustainability reporting that many institutional clients and government agencies now require from their contracted laboratories.

Should a lab buy a single-vendor or multi-vendor automation setup?

Most laboratories benefit from a multi-vendor automation setup, provided the systems are selected for genuine compatibility rather than convenience. A single-vendor approach simplifies support relationships but can limit technical options, while a well-integrated multi-vendor setup allows each stage of the sample preparation workflow to be covered by the most capable platform available for that specific task.

Sample preparation for environmental contaminants typically spans extraction, cleanup or purification, concentration, and evaporation. These are distinct processes with different technical requirements, and no single manufacturer dominates every stage equally. A laboratory that pairs a best-in-class extraction system with a dedicated automated cleanup platform and a high-throughput evaporation solution is likely to achieve better analytical performance than one constrained to a single vendor’s full portfolio.

The practical risk of multi-vendor setups is integration complexity and fragmented support. This risk is manageable when the laboratory works with a specialist distributor that represents multiple complementary manufacturers and can coordinate method development, installation, and troubleshooting across the full workflow. The key question is not single versus multi-vendor in the abstract, but whether the supplier relationship provides coherent support regardless of how many manufacturers are involved.

When should a laboratory reassess its automation investment?

A laboratory should reassess its automation investment when throughput consistently exceeds system capacity, when new regulatory requirements introduce analytes or methods the current platform cannot support, when solvent consumption or contamination incidents create compliance or quality risks, or when the cost of maintaining aging equipment approaches the cost of replacement.

These triggers rarely arrive as a single event. More often, reassessment is warranted when several smaller signals accumulate: longer turnaround times, increasing analyst intervention in nominally automated steps, difficulty sourcing consumables for older platforms, or the arrival of a major new contract that requires capabilities the current setup cannot deliver.

A structured reassessment should evaluate the current system against the laboratory’s three-to-five-year analytical roadmap, not just its present workload. If the pipeline includes PFAS expansion, new food safety matrices, or participation in government monitoring programs, the evaluation criteria must reflect those future demands. Lab automation longevity is ultimately determined by how well the original investment decision anticipated change, which is why reassessment is itself a form of future-proofing.

How DSP-Systems helps future-proof your laboratory automation investment

DSP-Systems provides laboratories in Europe and North America with a carefully selected portfolio of automated sample preparation systems designed for long-term operational relevance. Their offering addresses every stage of the analytical workflow and is built around the principles of scalability, regulatory compatibility, and sustainable chemistry.

Fully automated cleanup systems: The GO-EHT platform from Miura purifies samples for dioxins, PCBs, PBDEs, and PCNs across food, feed, soil, water, and air matrices, using less than 100 mL of solvent per sample and eliminating cross-contamination risk entirely.
High-capacity SPE automation: The SPE2000 processes up to 80 samples per run across 10 consecutive sequences, supports cartridges from 1 mL to 12 mL, and covers PFAS, pesticides, PAHs, and other emerging contaminants.
Large-volume water extraction: The AutoEmpore handles up to 12 channels in parallel or series mode, with automatic online filtration, supporting PFAS and pesticide analysis at scale.
Integrated extraction and concentration: The SER-158 extractor and the MultiVap and CentriVap evaporation systems complete the workflow from raw sample to injection-ready extract.
Method development and training: Beyond equipment supply, DSP-Systems supports laboratories with method validation, turnkey lab setups, and ongoing technical expertise across dioxins, PCBs, PFAS, pesticides, and more.

If you are evaluating your current automation setup or planning a new laboratory build, contact DSP-Systems to discuss which combination of systems best matches your analytical scope and long-term growth plans.

Veelgestelde vragen

How do I know which automated sample preparation system is the right starting point for my lab?

Start by mapping your current and anticipated analyte scope, sample matrices, and monthly throughput volumes, then match those parameters against system capacity and configurability. A platform that already supports the contaminant classes on your near-term roadmap — such as PFAS, dioxins, or pesticides — is a safer foundation than one optimized only for today’s workload. Working with a specialist distributor like DSP-Systems that can assess your full workflow and recommend complementary systems across extraction, cleanup, and concentration stages will give you a more coherent starting point than evaluating individual instruments in isolation.

What are the most common mistakes laboratories make when investing in automation?

The most common mistake is optimizing for purchase price rather than total cost of ownership over a realistic operational horizon of five to ten years. Laboratories that choose rigid, single-analyte systems to save upfront costs often face expensive revalidation, parallel system purchases, or full replacement within a few years when regulations expand or throughput demands grow. A second frequent error is underestimating the importance of vendor support — hardware alone does not future-proof a laboratory; ongoing method development assistance, training, and consumable availability are equally critical to long-term system performance.

Can automated SPE systems handle both routine high-volume testing and occasional specialized analyses on the same platform?

Yes, provided the system is designed with genuine configurability rather than fixed workflows. Platforms like the SPE2000 support a wide range of cartridge sizes, sample volumes, and analyte classes, allowing the same instrument to run large PFAS batches one day and smaller, more specialized pesticide or PAH extractions the next. The key is software-driven method switching and hardware flexibility — specifically, the ability to change rack configurations and cartridge formats without instrument downtime or dedicated hardware swaps.

How difficult is it to revalidate methods when regulations introduce new target compounds or lower detection limits?

Revalidation complexity depends heavily on how the original system was designed. On a flexible, software-configurable platform, adding new target compounds or adjusting extraction parameters to meet tighter detection limits is largely a method development exercise rather than a hardware problem, which significantly reduces both cost and turnaround time. On rigid, single-method systems, the same regulatory change can trigger full revalidation cycles or even equipment replacement. Partnering with a supplier that offers in-house method development support — as DSP-Systems does for dioxins, PCBs, PFAS, and pesticides — further accelerates this process by providing validated starting points rather than requiring laboratories to build methods from scratch.

What practical steps can a lab take right now to reduce solvent consumption without replacing existing equipment?

In the short term, laboratories can audit current extraction methods to identify steps where solvent volumes exceed what the analytical sensitivity actually requires, and then optimize wash and elution volumes through method development. Switching to smaller-format cartridges where sample volume allows and consolidating runs to minimize system priming and flush volumes are also immediately actionable. However, the most significant solvent reductions — such as eliminating dichloromethane entirely or dropping below 100 mL per sample — typically require platforms specifically engineered for low-solvent operation, making equipment evaluation a medium-term priority for labs with serious sustainability or compliance targets.

How should a laboratory evaluate vendor stability before committing to a long-term automation investment?

Look beyond the product brochure and assess the vendor’s track record in your specific analytical domain — how long have they supported the relevant analyte classes, and do they have documented installations in comparable laboratory environments? Ask specifically about consumable supply commitments, software update policies, and the availability of application support engineers for your region. A distributor that represents multiple established manufacturers and can coordinate support across a multi-vendor workflow, as DSP-Systems does across Europe and North America, provides an additional layer of continuity compared to relying on a single manufacturer’s direct sales and service structure.

Is green laboratory automation genuinely compatible with high analytical sensitivity, or does reducing solvents compromise performance?

Modern low-solvent automated systems are engineered to maintain or improve analytical sensitivity compared to traditional high-volume approaches, largely because reduced solvent volumes mean more concentrated final extracts and less opportunity for analyte loss during evaporation. Platforms that eliminate dichloromethane in favor of less aggressive solvents also reduce background interference in sensitive GC-MS and LC-MS/MS analyses. The compatibility of green chemistry with high sensitivity is well-established in validated methods for dioxins, PCBs, and PFAS — the practical challenge is selecting a system where solvent reduction is a core design principle rather than a marketing claim layered onto a conventional architecture.

Gerelateerde artikelen

Deze inhoud is gegenereerd met behulp van AI en kan fouten bevatten.